Integration of molecular pathology, epidemiology and social science for global precision medicine

Expert Review of Molecular Diagnostics

Volumn 16, Issue 1, 2016, Pages 11-23

  Nishi, Akihiro ^a   Milner, Danny A ^b,c   Giovannucci, Edward L ^b,c   Nishihara, Reiko ^c,d   Tan, Andy S ^c,d   Kawachi, Ichiro ^c   Ogino, Shuji ^b,c,d  

^a YALE UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

clinical outcome; disparity; epigenetics; interdisciplinary; molecular pathologic epidemiology; network analysis; personalized medicine; social medicine

Indexed keywords

DIAGNOSTIC IMAGING; HEALTH DISPARITY; HUMAN; MEDICAL PRACTICE; MEDICAL SOCIOLOGY; MOLECULAR DIAGNOSTICS; MOLECULAR EPIDEMIOLOGY; MOLECULAR MEDICINE; MOLECULAR PATHOLOGY; PERSONALIZED MEDICINE; REVIEW; SOCIAL BEHAVIOR; SOCIAL DETERMINANTS OF HEALTH; SOCIAL ENVIRONMENT; COLORECTAL NEOPLASMS; EPIGENETICS; GENETICS; GENOMICS; HEALTH CARE DELIVERY; PATHOLOGY;

COLORECTAL NEOPLASMS; DELIVERY OF HEALTH CARE; EPIGENOMICS; GENOMICS; HUMANS; PATHOLOGY, MOLECULAR; PRECISION MEDICINE;

EID: 84955176253     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2016.1115346     Document Type: Review

References (220)

1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372 (9):793-795.
2. Ashley EA. The precision medicine initiative: A new national effort. JAMA. 2015;313 (21):2119-2120.
3. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11 (5):550-560.
4. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health. 2005;95 (Suppl 1): S144-150.
5. Vanderweele TJ, Hernan MA. From counterfactuals to sufficient component causes and vice versa. Eur J Epidemiol. 2006;21 (12):855-858.
6. Hernan MA, Robins JM. Instruments for causal inference: An epidemiologist's dream? Epidemiology. 2006;17 (4):360-372.
7. Vanderweele TJ, Knol MJ. Interactions and complexity: goals and limitations. Epidemiol Methods. 2014;3 (1):79-81.
8. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32 (1):1-22.
9. Schatzkin A, Abnet CC, Cross AJ, et al. Mendelian randomization: how it can-and cannot-help confirm causal relations between nutrition and cancer. Cancer Prev Res (Phila). 2009;2 (2):104-113.
10. Sheehan NA, Didelez V, Burton PR, et al. Mendelian randomisation and causal inference in observational epidemiology. PLoS Med. 2008;5 (8):e177.
11. Taylor AE, Davies NM, Ware JJ, et al. Mendelian randomization in health research: using appropriate genetic variants and avoiding biased estimates. Econ Hum Biol. 2014;13:99-106.
12. Vanderweele TJ, Tchetgen Tchetgen EJ, Cornelis M, et al. Methodological challenges in mendelian randomization. Epidemiology. 2014;25 (3):427-435.
13. Thrift AP, Gong J, Peters U, et al. Mendelian randomization study of height and risk of colorectal cancer. Int J Epidemiol. 2015;44 (2):662-672.
14. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: The evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010;102 (6):365-367.
15. Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: An emerging transdisciplinary and interdisciplinary field. Gut. 2011;60 (3):397-411.
16. Ogino S, King EE, Beck AH, et al. Interdisciplinary education to integrate pathology and epidemiology: Towards molecular and population-level health science. Am J Epidemiol. 2012;176 (8):659-667.
17. Yankauer A. The relationship of fetal and infant mortality to residential segregation: An inquiry into social epidemiology. Am Sociol Review. 1950;15:644-648.
18. Berkman LF, Kawachi I. Social epidemiology. New York (NY): Oxford University Press; 2000.
19. Krieger N. Theories for social epidemiology in the 21st century: An ecosocial perspective. Int J Epidemiol. 2001;30 (4):668-677.
20. Oaks JM, Kaufman JS. Methods in social epidemiology. San Francisco: Jossey-Bass; 2006.
21. Berkman LF. Social epidemiology: social determinants of health in the United States: Are we losing ground? Annu Rev Public Health. 2009;30:27-41.
22. Galea S. Macrosocial determinants of population health. New York (NY): Springer; 2007.
23. Krieger N. Epidemiology and people's health. New York (NY): Oxford University Press; 2011.
24. Wilkinson RG, Pickett KE. Income inequality and population health: A review and explanation of the evidence. Social Science & Medicine. 2006;62 (7):1768-1784.
25. Kondo N, Sembajwe G, Kawachi I, et al. Income inequality, mortality, and self rated health: meta-analysis of multilevel studies. BMJ. 2009;339:b4471.
26. Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: A meta-analytic review. PLoS Med. 2010;7 (7):e1000316.
27. Uchino BN. Social support and health: A review of physiological processes potentially underlying links to disease outcomes. J Behav Med. 2006;29 (4):377-387.
28. Braveman PA, Cubbin C, Egerter S, et al. Socioeconomic status in health research: one size does not fit all. JAMA. 2005;294 (22):2879-2888.
29. Nishi A. Evolution and social epidemiology. Soc Sci Med. 2015;145:132-137.
30. Nishi A, Shirado H, Rand DG, et al. Inequality and visibility of wealth in experimental social networks. Nature. 2015;526 (7573):426-429.
31. Breen R, Chung I. Income inequality and education. Sociological Sci. 2015;2:454-477.
32. Bayer R, Galea S. Public Health in the Precision-Medicine Era. N Engl J Med. 2015;373 (6):499-501.
33. Porta M, Malats N, Vioque J, et al. Incomplete overlapping of biological, clinical, and environmental information in molecular epidemiological studies: A variety of causes and a cascade of consequences. J Epidemiol Community Health. 2002;56 (10):734-738.
34. Sherman ME, Howatt W, Blows FM, et al. Molecular pathology in epidemiologic studies: A primer on key considerations. Cancer Epidemiol Biomarkers Prev. 2010;19 (4):966-972.
35. Slattery ML. The science and art of molecular epidemiology. J Epidemiol Community Health. 2002;56 (10):728-729.
36. Bennett WP, Hussain SP, Vahakangas KH, et al. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol. 1999;187 (1):8-18.
37. Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer. 2015;15 (8):484-498.
38. Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013;26 (4):465-484.
39. Ogino S, Nishihara R, Vanderweele TJ, et al. Molecular pathological epidemiology is essential in studying neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology. Forthcoming.
40. Chatterjee N, Sinha S, Diver WR, et al. Analysis of cohort studies with multivariate and partially observed disease classification data. Biometrika. 2010;97 (3):683-698.
41. Chatterjee N. A two-stage regression model for epidemiological studies with multivariate disease classification data. J Am Stat Assoc. 2004;99:127-138.
42. Begg CB, Orlow I, Zabor EC, et al. Identifying etiologically distinct subtypes of cancer: A demonstration project involving breast cancer. Cancer Med. 2015;4 (9):1432-1439.
43. Begg CB, Seshan VE, Zabor EC, et al. Genomic investigation of etiologic heterogeneity: methodologic challenges. BMC Med Res Methodol. 2014;14:138.
44. Begg CB, Zabor EC. Detecting and exploiting etiologic heterogeneity in epidemiologic studies. Am J Epidemiol. 2012;176 (6):512-518.
45. Begg CB, Zabor EC, Bernstein JL, et al. A conceptual and methodological framework for investigating etiologic heterogeneity. Stat Med. 2013;32 (29):5039-5052.
46. Begg CB. A strategy for distinguishing optimal cancer subtypes. Int J Cancer. 2011;129 (4):931-937.
47. Wang M, Kuchiba A, Ogino S. A metaregression method for studying etiologic heterogeneity across disease subtypes classified by multiple biomarkers. Am J Epidemiol. 2015;182 (3):263-270.
48. Rosner B, Glynn RJ, Tamimi RM, et al. Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. Am J Epidemiol. 2013;178 (2):296-308.
49. Nishihara R, Vanderweele TJ, Shibuya K, et al. Molecular pathological epidemiology gives clues to paradoxical findings. Eur J Epidemiol. 2015;30 (10):1129-1135.
50. Lajous M, Bijon A, Fagherazzi G, et al. Body mass index, diabetes, and mortality in French women: explaining away a "paradox". Epidemiology. 2014;25 (1):10-14.
51. Banack HR, Kaufman JS. The obesity paradox: understanding the effect of obesity on mortality among individuals with cardiovascular disease. Prev Med. 2014;62:96-102.
52. Vanderweele TJ. Commentary: resolutions of the birthweight paradox: competing explanations and analytical insights. Int J Epidemiol. 2014;43 (5):1368-1373.
53. Ogino S, Lochhead P, Giovannucci E, et al. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: Power and promise of molecular pathological epidemiology. Oncogene. 2014;33 (23):2949-2955.
54. Field AE, Camargo CA, Ogino S. The merits of subtyping obestity: one size does not fit all. JAMA. 2013;310 (20):2147-2148.
55. Ikramuddin S, Livingston EH. New insights on bariatric surgery outcomes. JAMA. 2013;310 (22):2401-2402.
56. Van Winkel R. Aetiological stratification as a conceptual framework for gene-by-environment interaction research in psychiatry. Epidemiol Psychiatr Sci. 2015;24 (1):6-11.
57. Ogino S, Galon J, Fuchs CS, et al. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011;8 (12):711-719.
58. Song M, Nishihara R, Wang M, et al. Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut. 2015 DOI:10. 1136/gutjnl-2014-308852
59. Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T-cells in colorectal carcinoma. JAMA Oncol. 2015;1 (5):653-661.
60. Song M, Nishihara R, Wu K, et al. Marine omega-3 polyunsaturated fatty acids and risk of colorectal cancer according to microsatellite instability. J Natl Cancer Inst. 2015;107 (4):pii: djv007.
61. Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2015. DOI:10. 1136/gutjnl-2015-310101. [Epub ahead of print].
62. Mima K, Nishihara R, Nowak J, et al. MicroRNA MIR21 and T-cells in colorectal cancer. Cancer Immunology Res. 2015. DOI:10. 1158/2326-6066. CIR-15-0084. [Epub ahead of print].
63. Ito M, Kanno S, Nosho K, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer. 2015;137 (6):1258-1268.
64. Galon J, Franck P, Marincola FM, et al. Cancer classification using the immunoscore: A worldwide task force. J Transl Med. 2012;10 (1):205.
65. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the immunoscore in the classification of malignant tumors. J Pathol. 2014;232 (2):199-209.
66. Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal cancer. Nat Rev Dis Primers. 2015. DOI:10. 1038/ nrdp. 2015. 65. [Epub ahead of print].
67. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: Past, present and future. Patholog Res Int. 2011;2011:902674.
68. Hughes LA, Simons CC, Van Den Brandt PA, et al. Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One. 2011;6 (4):e18571.
69. Jacobs R, Voorneveld P, Kodach L, et al. Cholesterol metabolism and colorectal cancers. Curr Opin Pharmacol. 2012;12 (6):690-695.
70. Hughes LA, Khalid-De Bakker CA, Smits KM, et al. The CpG island methylator phenotype in colorectal cancer: Progress and problems. Biochimica Et Biophysica Acta. 2012;1825 (1):77-85.
71. Iwagami S, Baba Y, Watanabe M, et al. Pyrosequencing assay to measure LINE-1 methylation level in esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19 (8):2726-2732.
72. Limburg PJ, Limsui D, Vierkant RA, et al. Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women. Cancer Epidemiol Biomarkers Prev. 2012;21 (4):681-684.
73. Hughes LA, Williamson EJ, Van Engeland M, et al. Body size and risk for colorectal cancers showing BRAF mutation or microsatellite instability: A pooled analysis. Int J Epidemiol. 2012;41 (4):1060-1072.
74. Ku CS, Cooper DN, Wu M, et al. Gene discovery in familial cancer syndromes by exome sequencing: Prospects for the elucidation of familial colorectal cancer type X. Mod Pathol. 2012;25 (8):1055-1068.
75. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107 (9):1315-1329.
76. Koshiol J, Lin SW. Can tissue-based immune markers be used for studying the natural history of cancer? Ann Epidemiol. 2012;22 (7):520-530.
77. Fini L, Grizzi F, Laghi L. Adaptive and innate immunity, non clonal players in colorectal cancer progression. In: Ettarh R, editor. Colorectal cancer biology-from genes to tumor [Internet]. InTech; 2012 [cited 2015 Jul 1]. DOI:10. 5772/ 28146. ISBN: 978-953-51-0062-1. Available from: http://www. intechopen. com/books/colorectal-cancer-biologyfrom-genes-to-tumor/adaptive-andinnate-immunity-non-clonal-players-incolorectal-cancer-progression
78. Gay LJ, Mitrou PN, Keen J, et al. Dietary, lifestyle and clinico-pathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPIC-Norfolk Study. J Pathol. 2012;228 (3):405-415.
79. Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancerreinterpreting paradigms. Nat Rev Clin Oncol. 2012;9 (10):561-570.
80. Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012;18 (22):6169-6177.
81. Spitz MR, Caporaso NE, Sellers TA. Integrative cancer epidemiology-the next generation. Cancer Discov. 2012;2 (12):1087-1090.
82. Shanmuganathan R, Nazeema Banu B, Amirthalingam L, et al. Conventional and nanotechniques for DNA methylation profiling. J Mol Diagn. 2013;15 (1):17-26.
83. Rosty C, Young JP, Walsh MD, et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol. 2013;26 (6):825-834.
84. Weijenberg MP, Hughes LA, Bours MJ, et al. The mTOR pathway and the role of energy balance throughout life in colorectal cancer etiology and prognosis: unravelling mechanisms through a multidimensional molecular epidemiologic approach. Curr Nutr Rep. 2013;2 (1):19-26.
85. Buchanan DD, Win AK, Walsh MD, et al. Family history of colorectal cancer in BRAF p. V600E mutated colorectal cancer cases. Cancer Epidemiol Biomarkers Prev. 2013;22 (5):917-926.
86. Burnett-Hartman AN, Newcomb PA, Potter JD, et al. Genomic aberrations occuring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res. 2013;73 (9):2863-2872.
87. Alvarez MC, Santos JC, Maniezzo N, et al. MGMT and MLH1 methylation in Helicobacter pylori-infected children and adults. World J Gastroenterology: WJG. 2013;19 (20):3043-3051.
88. Hagland HR, Berg M, Jolma IW, et al. Molecular pathways and cellular metabolism in colorectal cancer. Dig Surg. 2013;30 (1):12-25.
89. Zaidi N, Lupien L, Kuemmerle NB, et al. Lipogenesis and lipolysis: The pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res. 2013;52 (4):585-589.
90. Abbenhardt C, Poole EM, Kulmacz RJ, et al. Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. Int J Mol Epidemiol Genet. 2013;4 (3):140-149.
91. Hughes LA, Melotte V, De Schrijver J, et al. The CpG island methylator phenotype: what's in a name? Cancer Res. 2013;73 (19):5858-5868.
92. Bae JM, Kim JH, Cho NY, et al. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer. 2013;109 (4):1004-1012.
93. Amirian ES, Petrosino JF, Ajami NJ, et al. Potential role of gastrointestinal microbiota composition in prostate cancer risk. Infect Agent Cancer. 2013;8 (1):42.
94. Hoffmeister M, Blaker H, Kloor M, et al. Body mass index and microsatellite instability in colorectal cancer: A population-based study. Cancer Epidemiol Biomarkers Prev. 2013;22 (12):2303-2311.
95. Araujo RF Jr., Lira GA, Guedes HG, et al. Lifestyle and family history influence cancer prognosis in Brazilian individuals. Pathol Res Pract. 2013;209 (12):753-757.
96. Esterhuyse MM, Kaufmann SH. Diagnostic biomarkers are hidden in the infected host's epigenome. Expert Rev Mol Diagn. 2013;13 (6):625-637.
97. Zhu Y, Yang SR, Wang PP, et al. Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. Br J Cancer. 2014;110 (5):1359-1366.
98. Hagland HR, Soreide K. Cellular metabolism in colorectal carcinogenesis: Influence of lifestyle, gut microbiome and metabolic pathways. Cancer Lett. 2015;356:273-280.
99. Shaheen NJ. Editorial: what is behind the remarkable increase in esophageal adenocarcinoma? Am J Gastroenterol. 2014;109 (3):345-347.
100. Brandstedt J, Wangefjord S, Nodin B, et al. Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability. BMC Cancer. 2014;14:371.
101. Coppede F. The role of epigenetics in colorectal cancer. Expert Rev Gastroenterol Hepatol. 2014;8 (8):935-948.
102. Bishehsari F, Mahdavinia M, Vacca M, et al. Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterology: WJG. 2014;20 (20):6055-6072.
103. Cross AJ, Moore SC, Boca S, et al. A prospective study of serum metabolites and colorectal cancer risk. Cancer. 2014;120 (19):3049-3057.
104. Simons CC, Van Den Brandt PA, Stehouwer C, et al. Body size, physical activity, early life energy restriction, and associations with methylated insulin-like growth factor binding protein genes in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2014;23 (9):1852-1862.
105. Haque TR, Bradshaw PT, Crockett SD. Risk factors for serrated polyps of the colorectum. Dig Dis Sci. 2014;59 (12):2874-2889.
106. Ryan BM, Wolff RK, Valeri N, et al. An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer. Cancer Epidemiol. 2014;38 (5):583-590.
107. Bragazzi NL. Ramadan fasting and biological biomarkers: The new opportunities of systems biology and omics sciences. In: Chtourou H, editor. Effects of ramadan fasting on health and athletic performance [Internet]. Omics group; 2014 [cited 2015 Jul 1]. Available from: http://www. esciencecentral. org/ebooks/effects-of-rama dan-fasting/biological-biomarkers. php
108. Hussain N. Epigenetics in childhood health and disease. In: Maulik N, Karagiannis T, editors. Molecular mechanisms and physiology of disease: implications for epigenetics and health [Internet]. New York (NY): Springer; 2014; p. 1-62. [cited 2015 Jul 1]. Available from: http://link. springer. com/ chapter/10. 1007%2F978-1-4939-0706-9-1
109. Li P, Wu H, Zhang H, et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: A meta-analysis. Gut. 2015;64 (9):1419-1425.
110. Huser V, Sincan M, Cimino JJ. Developing genomic knowledge bases and databases to support clinical management: current perspectives. Pharmgenomics Pers Med. 2014;7:275-283.
111. Wennersten C, Andersson G, Boman K, et al. Incident urothelial cancer in the Malmo Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker. Diagn Pathol. 2014;9 (1):189.
112. Mikeska T, Craig JM. DNA methylation biomarkers: cancer and beyond. Genes. 2014;5:821-864.
113. Campbell PT, Deka A, Briggs P, et al. Establishment of the cancer prevention study II nutrition cohort colorectal tissue repository. Cancer Epidemiol Biomarkers Prev. 2014;23 (12):2694-2702.
114. Wild CP, Bucher JR, De Jong BW, et al. Translational cancer research: balancing prevention and treatment to combat cancer globally. J Natl Cancer Inst. 2015;107 (1):353.
115. Caiazza F, Ryan EJ, Doherty G, et al. Estrogen receptors and their implications in colorecal carcinogenesis. Front Oncol. 2015;5. Article 19.
116. Ng JM, Yu J. Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. Int J Mol Sci. 2015;16:2472-2496.
117. Tillmans LS, Vierkant RA, Wang AH, et al. Associations between environmental exposures and incident colorectal cancer by ESR2 protein expression level in a population-based cohort of older women. Cancer Epidemiol Biomarkers Prev. 2015;24 (4):713-719.
118. Witvliet MI. World health survey: A useful yet underutilized global health data source. Austin J Public Health Epidemiol. 2014;1 (3):id1012.
119. Potter S. Body mass index 112 success secrets-112 most asked questions on body mass index-what you need to know [Internet]. Emeroe Publishing; 2014 [cited 2015 Jul 1]. Available from: http:// www. ebookmall. com/ebook/body-massindex-112-success-secrets-112-mostasked-questions-on-body-mass-indexwhat-you-need-to-know/sara-potter/ 9781488850356
120. Cisyk AL, Penner-Goeke S, Lichtensztejn Z, et al. Characterizing the prevalence of chromosome instability in interval colorectal cancer. Neoplasia. 2015;17 (3):306-316.
121. Weisenberger DJ, Levine AJ, Long TI, et al. Association of the colorectal CpG island methylator phenotype with molecular features, risk factors and family history. Cancer Epidemiol Biomarkers Prev. 2015;24 (3):512-519.
122. Gao C. Molecular pathological epidemiology: An interdisciplinary field for study of hepatocellular carcinoma. Austin J Gastroenterol. 2015;2 (3):1040.
123. Szylberg L, Janiczek M, Popiel A, et al. Serrated polyps and their alternative pathway to the colorectal cancer: A systematic review. Gastroenterol Res Pract. 2015;2015:ID 573814.
124. Wong EY, Chua C, Beh SY, et al. Addressing the needs of colorectal cancer survivors: current strategies and future directions. Expert Rev Anticancer Ther. 2015;15 (6):639-648.
125. Campbell PT, Newton CC, Newcomb PA, et al. Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. Cancer Epidemiol Biomarkers Prev. 2015;24 (8):1229-1238.
126. Mehta AM, Osse M, Kolkman-Uljee S, et al. Molecular background of ERAP1 downregulation in cervical carcinoma. Anal Cell Pathol. 2015;2015. Article ID 367837.
127. Miller KD, Simon M. Global perspectives on cancer: incidence, care, and experience. Abc-Clio. 2015. Online 761
128. De Ruijter TC, De Hoon JP, Slaats J, et al. Formalin-fixed, paraffin-embedded (FFPE) tissue epigenomics using Infinium HumanMethylation450 BeadChip assays. Lab Invest. 2015;95 (7):833-842.
129. Zakhari S, Hoek JB. Alcohol and breast cancer: reconciling epidemiological and molecular data. In: Vasiliou V, editor. Biological basis of alcohol-induced cancer. Switzerland: Springer International Publishing; 2015.
130. Kyriazis M. Translating laboratory antiaging biotechnology into applied clinical practice: Problems and obstacles. World J Transl Med. 2015. manuscript ID 17795
131. Cebola I, Custodio J, Munoz M, et al. Epigenetics override pro-inflammatory PTGS transcriptomic signature towards selective hyperactivation of PGE2 in colorectal cancer. Clin Epigenetics. 2015;7 (1):74.
132. Valdespino V, Valdespino PM. Potential of epigenetic therapies in the management of solid tumors. Cancer Manag Res. 2015;7:241-251.
133. Van Harten-Gerritsen AS, Balvers MGJ, Witkamp RF, et al. Vitamin D, inflammation and colorectal cancer progression: A review of mechanistic studies and future directions for epidemiological studies. Cancer Epidemiol Biomarkers Prev. 2015. DOI:10. 1158/1055-9965. EPI-15-0601. [Epub ahead of print].
134. Sylvetsky AC, Nandagopal R, Nguyen T, et al. Randomized clinical trial buddy study: Partners for better health in adolescents with type 2 diabetes. World J Diabetes. 2015
135. Ogino S. Molecular pathological epidemiology (MPE): overview of its paradigm and wide applicability even without tumor tissue [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD Cancer Prev Res (Phila). 2013;6 (11 suppl):CN06-01.
136. Kuller LH, Bracken MB, Ogino S, et al. The role of epidemiology in the era of molecular epidemiology and genomics: summary of the 2013 AJE-sponsored Society of Epidemiologic Research Symposium. Am J Epidemiol. 2013;178 (9):1350-1354.
137. Epplein M, Bostick RM, Mu L, et al. Challenges and opportunities in international molecular cancer prevention research: An ASPO Molecular Epidemiology and the Environment and International Cancer Prevention Interest Groups Report. Cancer Epidemiol Biomarkers Prev. 2014;23 (11):2613-2617.
138. Ogino S, Campbell PT, Nishihara R, et al. Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2015;26 (7):959-972.
139. Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012;12 (6):621-628.
140. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22 (2):292-298.
141. Tahara T, Yamamoto E, Suzuki H, et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 2014;74 (5):1311-1318.
142. Nishi A, Kawachi I, Koenen KC, et al. Lifecourse epidemiology and molecular pathological epidemiology. Am J Prev Med. 2015;48 (1):116-119.
143. Ijspeert JE, Vermeulen L, Meijer GA, et al. Serrated neoplasia-role in colorectal carcinogenesis and clinical implications. Nat Rev Gastroenterol Hepatol. 2015;12 (7):401-409.
144. Reimers MS, Zeestraten EC, Kuppen PJ, et al. Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep. 2013;1:166-183.
145. Zoratto F, Rossi L, Verrico M, et al. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. Tumour Biol. 2014;35 (7):6195-6206.
146. Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology. 2015;148 (6):1244-1260. e1216
147. Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology. 2015;149 (5):1204-1225.
148. Aleman JO, Eusebi LH, Ricciardiello L, et al. Mechanisms of obesity-induced gastrointestinal neoplasia. Gastroenterology. 2014;146 (2):357-373.
149. Lievre A, Blons H, Laurent-Puig P. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene. 2010;29 (21):3033-3043.
150. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27 (5):663-671.
151. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 2010;11 (8):753-762.
152. Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol. 2015;33 (16):1787-1796.
153. Chan AT, Ogino S, Fuchs CS. aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356 (21):2131-2142.
154. Nishihara R, Lochhead P, Kuchiba A, et al. Aspirin use and risk of colorectal cancer according to BRAFmutation status. JAMA. 2013;309 (24):2563-2571.
155. Nan H, Morikawa T, Suuriniemi M, et al. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst. 2013;105 (24):1852-1861.
156. Fink SP, Yamauchi M, Nishihara R, et al. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med. 2014;6 (233):233re232.
157. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. Jama. 2009;302 (6):649-658.
158. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation status, and colorectal cancer survival. N Engl J Med. 2012;367 (17):1596-1606.
159. Domingo E, Church DN, Sieber O, et al. Evaluation of PIK3CA mutation as a predictor of benefit from NSAID therapy in colorectal cancer. J Clin Oncol. 2013;31 (34):4297-4305.
160. Cathomas G. PIK3CA in colorectal cancer. Front Oncol. 2014;4:35.
161. Amatu A, Bencardino K, Sartore-Bianchi A, et al. Aspirin for colorectal cancer with PIK3CA mutations: The rising of the oldest targeted therapy? Annals Translational Med. 2013;1 (2):12.
162. KothariN, Kim R, Jorissen RN, et al. Impact of regular aspirin use on overall and cancerspecific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncol (Madr). 2015;54 (4):487-492.
163. Tougeron D, Sha D, Manthravadi S, et al. Aspirin and colorectal cancer: back to the future. Clin Cancer Res. 2014;20 (5):1087-1094.
164. Guilgen G. Reviewing the role of aspirin in chemoprevention of colorectal cancer. Curr Colorectal Cancer Rep. 2015;11 (3):105-111.
165. Fuchs CS, Ogino S. Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex! J Clin Oncol. 2013;31 (34):4358-4361.
166. Doubeni CA, Weinmann S, Adams K, et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: A nested casecontrol study. Ann Intern Med. 2013;158 (5 Pt 1):312-320.
167. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369 (12):1095-1105.
168. Brenner H, Chang-Claude J, Jansen L, et al. Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. Gastroenterology. 2014;146 (3):709-717.
169. Arain MA, Sawhney M, Sheikh S, et al. CIMP status of interval colon cancers: Another piece to the puzzle. Am J Gastroenterol. 2010;105:1189-1195.
170. Barrow TM, Michels KB. Epigenetic epidemiology of cancer. Biochem Biophys Res Commun. 2014;455 (1-2):70-83.
171. Suzuki H, Yamamoto E, Maruyama R, et al. Biological significance of the CpG island methylator phenotype. Biochem Biophys Res Commun. 2014;455 (1-2):35-42.
172. Sepulveda AR, Jones D, Ogino S, et al. CpG methylation analysis-current status of clinical assays and potential applications in molecular diagnostics: A report of the Association for Molecular Pathology. J Mol Diagn. 2009;11 (4):266-278.
173. Kim JH, KangGH. Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. World J Gastroenterol: WJG. 2014;20 (15):4230-4243.
174. Teodoridis JM, Hardie C, Brown R. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett. 2008;268 (2):177-186.
175. Li X, Hu F, Wang Y, et al. CpG island methylator phenotype and prognosis of colorectal cancer in Northeast China. Biomed Res Int. 2014;2014:236361.
176. Samowitz WS, Albertsen H, Sweeney C, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst. 2006;98 (23):1731-1738.
177. Limsui D, Vierkant RA, Tillmans LS, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst. 2010;102 (14):1012-1022.
178. Nishihara R, Morikawa T, Kuchiba A, et al. A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol. 2013;178 (1):84-100.
179. Curtin K, Samowitz WS, Wolff RK, et al. Somatic alterations, metabolizing genes and smoking in rectal cancer. Int J Cancer. 2009;125 (1):158-164.
180. Poynter JN, Haile RW, Siegmund KD, et al. Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev. 2009;18 (10):2745-2750.
181. Lindor NM, Yang P, Evans I, et al. Alpha-1-antitrypsin deficiency and smoking as risk factors for mismatch repair deficient colorectal cancer: A study from the colon cancer family registry. Mol Genet Metab. 2010;99 (2):157-159.
182. Chia VM, Newcomb PA, Bigler J, et al. Risk of microsatellite-unstable colorectal cancer is associated jointly with smoking and nonsteroidal anti-inflammatory drug use. Cancer Res. 2006;66 (13):6877-6883.
183. Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology. 2015;149 (5):1177-1190. e1173
184. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011;8 (12):686-700.
185. Colussi D, Brandi G, Bazzoli F, et al. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci. 2013;14:16365-16385.
186. Lin JH, Giovannucci E. Environmental exposure and tumor heterogeneity in colorectal cancer risk and outcomes. Curr Colorectal Cancer Rep. 2014;10:94-104.
187. Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. Cancers. 2013;5:676-713.
188. Dahlin AM, Palmqvist R, Henriksson ML, et al. The role of the CpG Island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res. 2010;16 (6):1845-1855.
189. O'brien MJ, Zhao Q, Yang S. Colorectal serrated pathway cancers and precursors. Histopathology. 2015;66 (1):49-65.
190. Carlson JW, Lyon E, Walton D, et al. Partners in pathology: A collaborative model to bring pathology to resource poor settings. Am J Surg Pathol. 2010;34 (1):118-123.
191. Rubin EH, Allen JD, Nowak JA, et al. Developing precision medicine in a global world. Clin Cancer Res. 2014;20 (6):1419-1427.
192. African Strategies for Advancing Pathology Group M. Quality pathology and laboratory diagnostic services are key to improving global health outcomes: improving global health outcomes is not possible without accurate disease diagnosis. Am J Clin Pathol. 2015;143 (3):325-328.
193. Clegg LX, Reichman ME, Miller BA, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control. 2009;20 (4):417-435.
194. Ayanian JZ, Carethers JM. Bridging behavior and biology to reduce socioeconomic disparities in colorectal cancer risk. J Natl Cancer Inst. 2012;104 (18):1343-1344.
195. Morikawa T, Kuchiba A, Yamauchi M, et al. Association of CTNNB1 (betacatenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA. 2011;305 (16):1685-1694.
196. Morikawa T, Kuchiba A, Lochhead P, et al. Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with beta-catenin (CTNNB1) status. Cancer Res. 2013;73 (5):1600-1610.
197. Lee J, Jeon JY, Meyerhardt JA. Diet and lifestyle in survivors of colorectal cancer. Hematol Oncol Clin North Am. 2015;29 (1):1-27.
198. Strully KW, Fowler JH, Murabito JM, et al. Aspirin use and cardiovascular events in social networks. Social Science & Medicine. 2012;74 (7):1125-1129.
199. Davison KK, Nishi A, Kranz S, et al. Associations among social capital, parenting for active lifestyles, and youth physical activity in rural families living in upstate New York. Social Science & Medicine. 2012;75 (8):1488-1496.
200. Ademuyiwa FO, Edge SB, Erwin DO, et al. Breast cancer racial disparities: unanswered questions. Cancer Res. 2011;71 (3):640-644.
201. Ambrosone CB, Zirpoli GR, Bovbjerg DH, et al. Associations between estrogen receptor-negative breast cancer and timing of reproductive events differ between African American and European American women. Cancer Epidemiol Biomarkers Prev. 2014;23 (6):1115-1120.
202. Chandran U, Zirpoli G, Ciupak G, et al. Racial disparities in red meat and poultry intake and breast cancer risk. Cancer Causes Control. 2013;24 (12):2217-2229.
203. Quan L, Gong Z, Yao S, et al. Cytokine and cytokine receptor genes of the adaptive immune response are differentially associated with breast cancer risk in American women of African and European ancestry. Int J Cancer. 2014;134 (6):1408-1421.
204. Phipps AI, Ahnen DJ, Cheng I, et al. PIK3CA somatic mutation status in relation to patient and tumor factors in racial/ethnic minorities with colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2015;24 (7):1046-1051.
205. Palmer JR, Viscidi E, Troester MA, et al. Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl Cancer Inst. 2014;106 (10):dju237.
206. Ambrosone CB, Young AC, Sucheston LE, et al. Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry. Oncotarget. 2014;5 (1):237-248.
207. Mokarram P, Kumar K, Brim H, et al. Distinct high-profile methylated genes in colorectal cancer. PLoS One. 2009;4 (9): e7012.
208. Ashktorab H, Daremipouran M, Goel A, et al. DNA methylome profiling identifies novel methylated genes in African American patients with colorectal neoplasia. Epigenetics off J DNA Methylation Soc. 2014;9 (4):503-512.
209. Xia YY, Ding YB, Liu XQ, et al. Racial/ ethnic disparities in human DNA methylation. Biochimica Et Biophysica Acta. 2014;1846 (1):258-262.
210. Vogtmann E, Shanmugam C, Katkoori VR, et al. Socioeconomic status, p53 abnormalities, and colorectal cancer. J Gastrointest Oncol. 2013;4 (1):40-44.
211. Baker L, Quinlan PR, Patten N, et al. p53 mutation, deprivation and poor prognosis in primary breast cancer. Br J Cancer. 2010;102 (4):719-726.
212. Gordon NH. Association of education and income with estrogen receptor status in primary breast cancer. Am J Epidemiol. 1995;142 (8):796-803.
213. Taylor A, Cheng KK. Social deprivation and breast cancer. J Public Health Med. 2003;25 (3):228-233.
214. Brown M, Tsodikov A, Bauer KR, et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptornegative, invasive breast cancer: The California Cancer Registry, 1999-2004. Cancer. 2008;112 (4):737-747.
215. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triplenegative phenotype: A population-based study from the California cancer Registry. Cancer. 2007;109 (9):1721-1728.
216. Parise CA, Bauer KR, Brown MM, et al. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009;15 (6):593-602.
217. KhouryMJ, GwinnML, Glasgow RE, et al. A population approach to precision medicine. Am J Prev Med. 2012;42 (6):639-645.
218. Wuchty S, Jones BF, Uzzi B. The increasing dominance of teams in production of knowledge. Science. 2007;316 (5827):1036-1039.
219. Sharp PA, Langer R. Research agenda. Promoting convergence in biomedical science. Science. 2011;333 (6042):527.
220. Spitz MR, Lam TK, Schully SD, et al. The next generation of large-scale epidemiologic research: implications for training cancer epidemiologists. Am J Epidemiol. 2014;180 (10):964-967.